or Try an Advanced Search...

    Orphan Disease Stocks List

    Symbol Grade Name % Change
    FOLD F Amicus Therapeutics, Inc. -0.89
    CYCN F Cyclerion Therapeutics, Inc. -11.96
    FATE F Fate Therapeutics, Inc. -5.41
    SEEL F Seelos Therapeutics, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Lysosomal Storage Disorder Lysosomal Storage Disorders Medicine Adult Stem Cell Biology Biotechnology Blood Cells Cardiomyopathy Central Nervous System Disease Cord Blood Diabetic Nephropathy Disease Disorders Enzyme Replacement Therapy Enzymes Fabry Disease Gaucher Disease Heart Failure Hematologic Malignancies

    Related ETFs - A few ETFs which own one or more of the above listed Orphan Disease stocks.

    Symbol Grade Name Weight
    WDNA D WisdomTree BioRevolution Fund 2.41
    SOVF B Sovereign's Capital Flourish Fund 1.95
    SBIO C ALPS Medical Breakthroughs ETF 1.95
    BBP C BioShares Biotechnology Products Fund 1.37
    GURU B Global X Top Guru Holdings Index ETF 1.18
    View all Orphan Disease ETFs...
    Compare ETFs
    Compare SBIO to GURU Compare WDNA to BBP Compare WDNA to SBIO

        Orphan Disease Stocks Recent News

        Date Stock Title
        Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
        Nov 19 FOLD HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
        Nov 19 FATE Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
        Nov 18 FATE Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
        Nov 18 FATE Fate stock rallies 37% on positive Phase 1 data for FT819, FT522
        Nov 18 FATE Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
        Nov 18 FATE Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
        Nov 15 FATE Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Lysosomal Storage Disorder Lysosomal Storage Disorders Medicine Adult Stem Cell Biology Biotechnology Blood Cells Cardiomyopathy Central Nervous System Disease Cord Blood Diabetic Nephropathy Disease Disorders Enzyme Replacement Therapy Enzymes Fabry Disease Gaucher Disease Heart Failure Hematologic Malignancies
        Orphan Disease

        Orphan diseases are rare medical conditions that affect a small percentage of the population. They are often genetic in nature and can be life-threatening or chronically debilitating. Orphan diseases are often under-researched and underfunded, making it difficult to find treatments or cures.

        Browse All Tags